z-logo
open-access-imgOpen Access
Persisting chemosensory impairments in 366 healthcare workers following COVID-19: an 11-month follow-up
Author(s) -
Nicholas Bussière,
Jie Mei,
Cindy Lévesque-Boissonneault,
Mathieu Blais,
Sara Carazo,
François GrosLouis,
Robert Laforce,
Gaston De Serres,
Nicolas Dupré,
Johannes Frasnelli
Publication year - 2022
Publication title -
chemical senses
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.856
H-Index - 100
eISSN - 1464-3553
pISSN - 0379-864X
DOI - 10.1093/chemse/bjac010
Subject(s) - olfaction , intraclass correlation , olfactory system , visual analogue scale , audiology , medicine , covid-19 , anosmia , psychology , physical therapy , psychometrics , neuroscience , clinical psychology , psychiatry , disease , infectious disease (medical specialty)
Olfactory and gustatory dysfunctions (OD, GD) are prevalent symptoms following COVID-19 and persist in 6%-44% of individuals post-infection. As only few reports have described their prognosis after 6 months, our main objective was to assess the prevalence of OD and GD 11-month post-COVID-19. We also aimed to determine intraclass correlation coefficients (ICC) of chemosensory self-ratings for the follow-up of chemosensory sensitivity. We designed an observational study and distributed an online questionnaire assessing chemosensory function to healthcare workers with a RT-PCR-confirmed SARS-CoV-2 infection 5- and 11-month post-COVID-19. Specifically, we assessed olfaction, gustation, and trigeminal sensitivity (10-point visual analog scale) and function (4-point Likert scale). We further measured clinically relevant OD using the Chemosensory Perception Test, a psychophysical test designed to provide a reliable remote olfactory evaluation. We included a total of 366 participants (mean [SD] age of 44.8 (11.7) years old). They completed the last online questionnaire 10.6 months (0.7) after the onset of COVID-19 symptoms. Of all participants, 307 (83.9%) and 301 (82.2%) individuals retrospectively reported lower olfactory or gustatory sensitivity during the acute phase of COVID-19. At the time of evaluation, 184 (50.3%) and 163 (44.5%) indicated reduced chemosensory sensitivity, 32.2% reported impairment of olfactory function while 24.9% exhibited clinically relevant OD. Olfactory sensitivity had a high test-retest reliability (ICC: 0.818; 95% CI: 0.760-0.860). This study suggests that chemosensory dysfunctions persist in a third of COVID-19 patients 11 months after COVID-19. OD appears to be a common symptom of post-COVID-19 important to consider when treating patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom